Mitchell David A, Lambert Gavin, Secher Niels H, Raven Peter B, van Lieshout Johannes, Esler Murray D
Human Neurotransmitter Laboratory, Baker Medical Research Institute, Prahran, Victoria, Australia.
J Physiol. 2009 Jun 1;587(Pt 11):2589-97. doi: 10.1113/jphysiol.2008.167999. Epub 2009 Apr 29.
A novel neurochemical method was applied for studying the activity of sympathetic nerves in the human cerebral vascular system. The aim was to investigate whether noradrenaline plasma kinetic measurements made with internal jugular venous sampling reflect cerebrovascular sympathetic activity. A database was assembled of fifty-six healthy subjects in whom total body noradrenaline spillover (indicative of whole body sympathetic nervous activity), brain noradrenaline spillover and brain lipophlic noradrenaline metabolite (3,4-dihydroxyphenolglycol (DHPG) and 3-methoxy-4-hydroxyphenylglycol (MHPG)) overflow rates were measured. These measurements were also made following ganglion blockade (trimethaphan, n = 6), central sympathetic inhibition (clonidine, n = 4) and neuronal noradrenaline uptake blockade (desipramine, n = 13) and in a group of patients (n = 9) with pure autonomic failure (PAF). The mean brain noradrenline spillover and brain noradrenaline metabolite overflow in healthy subjects were 12.5 +/- 1.8, and 186.4 +/- 25 ng min(-1), respectively, with unilateral jugular venous sampling for both. Total body noradrenaline spillover was 605.8 ng min(-1) +/- 34.4 ng min(-1). As expected, trimethaphan infusion lowered brain noradrenaline spillover (P = 0.03), but perhaps surprisingly increased jugular overflow of brain metabolites (P = 0.01). Suppression of sympathetic nervous outflow with clonidine lowered brain noradrenaline spillover (P = 0.004), without changing brain metabolite overflow (P = 0.3). Neuronal noradrenaline uptake block with desipramine lowered the transcranial plasma extraction of tritiated noradrenaline (P = 0.001). The PAF patients had 77% lower brain noradrenaline spillover than healthy recruits (P = 0.06), indicating that in them sympathetic nerve degeneration extended to the cerebral circulation, but metabolites overflow was similar to healthy subjects (P = 0.3). The invariable discordance between noradrenline spillover and noradrenaline metabolite overflow from the brain under these different circumstances indicates that the two measures arise from different sources, i.e. noradrenaline spillover originates from the cerebral vasculature outside the blood-brain barrier, and the noradrenaline metabolites originate primarily from brain noradrenergic neurons. We suggest that measurements of transcranial plasma noradrenaline spillover have utility as a method for assessing the sympathetic nerve activity of the cerebral vasculature.
一种新型神经化学方法被应用于研究人类脑血管系统中交感神经的活性。目的是调查通过颈内静脉采样进行的去甲肾上腺素血浆动力学测量是否反映脑血管交感神经活性。收集了56名健康受试者的数据库,测量了他们的全身去甲肾上腺素溢出量(指示全身交感神经活性)、脑去甲肾上腺素溢出量以及脑脂溶性去甲肾上腺素代谢物(3,4 - 二羟基苯乙二醇(DHPG)和3 - 甲氧基 - 4 - 羟基苯乙二醇(MHPG))的溢出率。在进行神经节阻断(三甲噻芬,n = 6)、中枢交感神经抑制(可乐定,n = 4)和神经元去甲肾上腺素摄取阻断(地昔帕明,n = 13)后以及在一组纯自主神经功能衰竭(PAF)患者(n = 9)中也进行了这些测量。对于健康受试者,单侧颈内静脉采样时,平均脑去甲肾上腺素溢出量和脑去甲肾上腺素代谢物溢出量分别为12.5±1.8和186.4±25 ng min⁻¹。全身去甲肾上腺素溢出量为605.8 ng min⁻¹±34.4 ng min⁻¹。正如预期的那样,输注三甲噻芬降低了脑去甲肾上腺素溢出量(P = 0.03),但可能令人惊讶的是增加了脑代谢物的颈静脉溢出量(P = 0.01)。可乐定抑制交感神经传出降低了脑去甲肾上腺素溢出量(P = 0.004),而未改变脑代谢物溢出量(P = 0.3)。地昔帕明阻断神经元去甲肾上腺素摄取降低了氚标记去甲肾上腺素的经颅血浆提取率(P = 0.001)。PAF患者的脑去甲肾上腺素溢出量比健康受试者低77%(P = 0.06),表明他们的交感神经退变扩展到了脑循环,但代谢物溢出量与健康受试者相似(P = 0.3)。在这些不同情况下,脑去甲肾上腺素溢出量与脑去甲肾上腺素代谢物溢出量之间始终不一致,这表明这两种测量来自不同来源,即去甲肾上腺素溢出源于血脑屏障外的脑血管,而去甲肾上腺素代谢物主要源于脑去甲肾上腺素能神经元。我们认为经颅血浆去甲肾上腺素溢出量的测量作为评估脑血管交感神经活性的一种方法具有实用性。